OSE IMMUNOTHERAPEUTICS |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.65 EUR | +1.46% |
|
+13.33% | +78.74% |
| 17/04 | OSE: licensing agreement with AbbVie enters into force | CF |
| 17/04 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Other Biotechnology & Medical Research | +1.46% | +13.33% | +78.74% | +104.82% | +101.32% | 177M |  | | |
Technical Rankings Surperformance
- Stock Market
- Equities
- OSE Stock
- Charts OSE Immunotherapeutics
- Comparison Chart
